Issledovanie III fazy: znachitel'noe uvelichenie prodolzhitel'nosti zhizni u patsientov s naibolee rasprostranennym tipom nemelkokletochnogo raka legkogo, poluchavshikh prodolzhennuyu podderzhivayushchuyu terapiyu na osnove preparata Alimta
- Authors: - -
- Issue: Vol 14, No 2 (2012)
- Pages: 5-
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/29470
- ID: 29470
Cite item
Full Text
Abstract
References
- Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
- Ciuleanu T et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374 (9699): 1432-40.
- Paz-Ares LG et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29: abstract CRA 7510.